greeksoup/ stock research
Stock research / United States / RDY / Year to 31 March 2022

Dr. Reddy’s Laboratories Limited (RDY) annual results, year to 31 March 2022: revenue INR 214,391 million, from the 20-F

Dr. Reddy’s Laboratories Limited files a 20-F with the SEC once a year, in Indian rupees. In the year to 31 March 2022 it reported revenue of INR 214,391 million ($2.9 billion at the year's average rate), up 13.0% on the year before. Its profit attributable to shareholders was INR 23,568 million, up 36.7%, and diluted earnings per share INR 141.69.

Revenue
INR 214,391 million
+13.0% on the year
FY2016FY2022
Operating margin
13.7%
12.8% a year earlier
FY2016FY2022
Net income
INR 23,568 million
+36.7% on the year
FY2016FY2022
Diluted EPS
INR 141.69
+36.7% on the year
FY2016FY2022

this yearthe year beforeIn Indian rupees as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2021Mar 2022
Revenue189,722214,391
Cost of sales86,645100,551
Gross profit103,077113,840
Research and development16,54117,482
Selling, general and administrative54,65062,081
Operating profit24,28029,476
Finance costs970958
Profit before tax26,41332,298
Income tax9,1758,730
Profit for the year17,23823,568
Profit attributable to shareholders17,23823,568
Filing20-F20-F
INR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2021Mar 2022
Diluted EPS103.65141.69
Basic EPS103.94142.08
Filing20-F20-F

INR per ordinary share, as filed.

Cash flow

Year toMar 2021Mar 2022
Cash from operations35,70328,108
Purchase of property, plant and equipment9,74114,660
Free cash flow25,96213,448
Cash from investing-22,660-26,387
Cash from financing-298-2,422
Depreciation and amortisation12,79611,824
Buybacks1,1930.0
Dividends paid4,1474,146
Filing20-F20-F

INR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2021Mar 2022
Funded by
Equity attributable to shareholders173,062190,527
Borrowings, as filed30,29933,845
Lease liabilities3,363n/a
Other liabilities58,76768,455
Total equity and liabilities265,491292,827
Owned
Property, plant and equipment57,11162,169
Goodwill4,5684,418
Other intangible assets35,64827,246
Cash and cash equivalents14,82914,852
Trade and other receivables49,64166,764
Inventories45,41250,884
Other assets58,28266,494
Total assets265,491292,827
Filing20-F20-F

INR million, at each fiscal year end.

Ratios on the filed lines

Year toMar 2021Mar 2022
Gross margin54.3%53.1%
Operating margin12.8%13.7%
Net margin9.1%11.0%
Free cash flow margin13.7%6.3%
Return on year-end equity10.0%12.4%
Effective tax rate34.7%27.0%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2022, filed 12 June 2024: the filing. The figures are in Indian rupees as filed.